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Objectives: Pulmonary hypertension is a life-threatening disease, and alternative strategies are essential for patients
with critical pulmonary hypertension.We developed a new procedure using microgelatin hydrogel microspheres in-
corporating basicfibroblast growth factor (mGHMs/bFGF) for intratracheal administration and evaluated the effect of
a single intratracheal administration ofmGHMs/bFGF on rats withmonocrotaline-induced pulmonary hypertension.
Methods: Monocrotaline was injected into 54 rats simultaneously with intratracheal administration of plain
mGHMs (vehicle group), bFGF in solution form (free-bFGF group), mGHMs/bFGF (mGHMs/bFGF group),
and plain saline with subcutaneous injection of saline instead of monocrotaline (control group, n ¼ 18). Three
weeks after the administration, 48 rats (n ¼ 12 from each group) were subjected to hemodynamic and histologic
evaluations. Survival was assessed in 6 rats of each group 10 weeks after the intratracheal administration.
Results: The mGHMs/bFGF group showed significantly lower right ventricular/left ventricular pressure ratios at
3 weeks than the vehicle and free-bFGF groups (0.35  0.04, 0.54  0.11, 0.58  0.21, and 0.36  0.05 for the
control, vehicle, free-bFGF, and mGHMs/bFGF groups, respectively; P< .01). Histologically, the mGHMs/
bFGF group had a significantly higher number of vessels (diameter 50 mm) than the other groups (5.3 
2.6, 4.6  2.8, 7.3  2.5, and 18.9  7.0 vessels/mm2, respectively; P< .01). Ten weeks after the intratracheal
administration, 6 (100.0%) rats had survived in the control group, and 1 (16.7%) survived in the vehicle, 0 (0%)
in the free-bFGF, and 5 (83.3%) in the mGHMs/bFGF groups (n ¼ 6 each).
Conclusions:A single intratracheal administration of mGHMs/bFGF increased the number of vessels in the lung
and ameliorated survival and hemodynamics in rats with monocrotaline-induced pulmonary hypertension.Pulmonary hypertension (PH) is a life-threatening disease
characterized by progressive pulmonary arterial hyperten-
sion and increases in pulmonary vascular resistance that
lead to right ventricular (RV) failure.1 Recently, survival
and quality of life have improved in patients with PH
because of the development of pharmacologic therapies,
such as novel types of prostacyclin,2,3 endothelin receptor
blockers,4,5 and phosphodiesterase inhibitors.6,7 However,
these pharmacologic effects might be transient or not suffi-
cient for the severely damaged pulmonary vessels, such as
critical PH. Thus alternative strategies are essential for
patients with critical PH.
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doi:10.1016/j.jtcvs.2008.05.0381250 The Journal of Thoracic and Cardiovascular SBasic fibroblast growth factor (bFGF) is not only a potent
angiogenic mitogen of various kinds of cells but also a cyto-
kine that can stimulate tissue regeneration.8-10We developed
a biodegradable hydrogel made from acidic gelatin as the
slow-release carrier for bFGF and demonstrated that sus-
tained release of bFGF with biodegradable gelatin hydrogels
enhanced angiogenesis and arteriogenesis in various cardio-
vascular areas.11-14 Although the angiogenic and arterio-
genic properties of bFGF can ameliorate severe PH, the
optimal deliverymethod to the lung has not been established.
In the study presented here, we used newly developedmicro-
gelatin hydrogel microspheres (mGHMs) that make intratra-
cheal administration possible.
We used rats with monocrotaline (MCT)-induced PH to
test the hypothesis that a single intratracheal administration
of mGHMs incorporating bFGF (mGHMs/bFGF) could
enhance both angiogenesis and arteriogenesis in the lung
and ameliorate progressive PH.
MATERIALS AND METHODS
Preparation of mGHMs/bFGF
Gelatin with an isoelectric point of 4.9 was isolated from bovine bone
collagen by using an alkaline process with Ca(OH)2 (Nitta Gelatin Co,
Osaka, Japan). Human recombinant bFGF with an isoelectric point of 9.6urgery c November 2008
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PAbbreviations and Acronyms
bFGF ¼ basic fibroblast growth factor
LV ¼ left ventricle
MCT ¼ monocrotaline
mGHM ¼ microgelatin hydrogel
microsphere
mGHMs/bFGF ¼ microgelatin hydrogel
microspheres incorporating basic
fibroblast growth factor
PH ¼ pulmonary hypertension
RV ¼ right ventricle
was purchased from Kaken Pharmaceutical Co, Ltd (Tokyo, Japan).
mGHMs with a diameter of approximately 10 mm were made as previously
described15 and impregnated with an aqueous solution containing 100 mg of
bFGF and mGHMs/bFGF. All experimental procedures were conducted
under sterile conditions.
Animals
Male Wistar rats weighing 200 to 220 g were used in this study. All
animals received humane care in compliance with the ‘‘Principles of labo-
ratory animal care’’ formulated by the National Society for Medical
Research and the ‘‘Guide for the care and use of laboratory animals’’ pre-
pared by the Institute of Laboratory Animal Resources, National Research
Council, and published by the National Academy Press.
Experimental PH Model
MCT (300 mg, Crotaline; Sigma, St Louis, Mo) was dissolved in 1.8 mL
of 1 mol/L HCl, followed by the addition of 3 to 4 mL of distilled water.16
This solution was then adjusted to pH 7.4 with 1 mol/L NaOH solution and
topped up to 15 mL with distilled water. Each rat was anesthetized with an
intraperitoneal injection of sodium pentobarbital (30 mg/kg) and received
a single subcutaneous injection of MCT solution (60 mg/kg) in the neck.
After this injection, PH gradually progressed and was completed approxi-
mately 3 weeks after the injection,16 whereas lung tissues displayed intersti-
tial thickening accompanied by prominent medial hypertrophy of the
muscular pulmonary artery and arterioles.17
Release Profile of bFGF From mGHMs in Lung
Tissue After Intratracheal Administration
The intrapulmonary release profile of bFGF from mGHMs after intratra-
cheal administration was evaluated in 30 healthy rats. The rats were anesthe-
tized as described above, and mGHMs incorporating iodine 125–labeled
bFGF (100mg/0.1mL)were injected into the trachea of 15 rats with a pulmo-
nary drug delivery device (Micro Sprayer IA-1B; LMS Co, Ltd, Tokyo, Ja-
pan; mGHMs/bFGF group, n¼ 15). In the other 15 rats, iodine 125–labeled
bFGF solution (100 mg/0.1 mL) was injected into the trachea with the same
device (free-bFGFgroup, n¼ 15). Bilateral pulmonary tissueswere obtained
2 hours and 3, 7, 10, and 14 days after the intratracheal administration (n¼ 3
for each time point). The radioactivity remaining in each lung was measured
with a gamma counter (ARC-301B; Aloka, Tokyo, Japan).
Prevention of Progression of PH by mGHMs/bFGF
Just after the MCT injection, 54 rats were randomized to one of 3 groups
(n ¼ 18 each) and underwent intratracheal administration of the following
solutions: 0.1 mL of saline containing free mGHMs (vehicle group), 0.1
mL of saline containing 100 mg of bFGF (free-bFGF group), and 0.1 mL
of saline containing mGHMs incorporating 100 mg of bFGF (mGHMs/The Journal of Thoracic and CbFGF group). The remaining 18 rats received a single subcutaneous injec-
tion of saline instead of MCT, followed by intratracheal administration of
0.1 mL of saline (control group). Three weeks after the administration, 12
rats from each group were subjected to hemodynamic and histologic evalu-
ations. Survival was assessed in 6 rats of each group 10weeks after the intra-
tracheal administration.
Measurement of Hemodynamic Parameters
and Assessment of RV Hypertrophy
Three weeks after the intratracheal administration, rats were anesthetized
and mechanically ventilated (fraction of inspired oxygen, 0.21; respiratory
rate, 60 breaths/min). After the heart was exposed after median sternotomy,
systolic pressures of the RV and left ventricle (LV) were measured by means
of puncture with a 23-gauge needle. The rats were then killed by means of in-
travenous administrationof a lethal dose of sodiumpentobarbital, and theheart
and bilateral lungs were thoroughly washed with saline and sampled en bloc
under pressurization through an intubation catheter. To assess RV hypertro-
phy, the RV free wall was dissected from the LV and septum, and they
were weighed separately with an analytic scale. Lungs were fixed with 10%
paraformaldehyde solution in PBS solution for histologic examination.
Arterial Blood Gas Analysis
In conjunction with the hemodynamic studies, an arterial blood sample
of approximately 0.2 mL was obtained from the needle inserted into the
LV and subjected to blood gas analysis.
Histopathology
For the production of paraffin sections, the lung tissuewas fixed in forma-
lin for 24 hours at room temperature, dehydrated in ethanol, and embedded in
a paraffin block. Sections were cut into 3-mm-thick specimens and stained
with hematoxylin and eosin. Tissue sections were also immunostained
with antibodies against von Willebrand factor (an endothelial marker). Nor-
mal immunoglobulin fractions were used as a negative control to determine
antibody specificity. Five fields were randomly selected in each sample, and
the numbers of vessels (50 mm diameter) and small vessels, capillaries, or
both (diameter<50 mm) per square millimeter were counted manually by 2
pathologists who were unaware of the treatment groups. Medial wall thick-
nesswas also assessed as the percentage ofmedialwall thickness by 2 pathol-
ogists using elastica van Gieson stain, as described previously.18
Statistical Analysis
All data was expressed as means  standard deviations and as ranges.
Differences between groups were assessed bymeans of analysis of variance,
followed by post hoc comparisons with the Bonferroni/Dunn method. Sig-
nificance of differences in survival data were determined by means of the
Kaplan–Meier analysis and compared by using log-rank tests. Statview soft-
ware (Abacus Concepts, Inc, Berkeley, Calif) was used for all statistical
analyses.
RESULTS
Release Profile of bFGF From mGHMs in the Lung
After Intratracheal Administration
None of the mice died after the intratracheal administra-
tion of free-bFGF or mGHMs/bFGF. bFGF was distributed
equally in both the mGHMs and mGHMs/bFGF groups in
terms of the volume in each lobe of the lung.(Radioactivity
remaining in the right upper lobe, right middle lobe, right
lower lobe, left upper lobe, and left lower lobe of total
lung 2 hours after the intratracheal administration was
10.5%  3.9%, 11.3%  5.5%, 24.6%  8.4%, 43.8%ardiovascular Surgery c Volume 136, Number 5 1251
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P 17.6%, and 9.9%  2.9%, respectively). Radioactivity
remaining in the whole lung in the free-bFGF group at 2
hours and 3, 7, 10, and 14 days after administration was
67.6%  12.6%, 7.6%  2.2%, 2.0%  1.2%, 0.9% 
0.1%, and 0.1% 0.0%, respectively. Corresponding find-
ings for the mGHMs/bFGF group were 71.6%  7.2%,
23.1%  1.6%, 8.3%  2.4%, 6.1%  1.6%, and 5.4%
 3.1% (Figure 1). Radioactivity of bFGF remaining in
the mGHMs/bFGF group was significantly higher than
that in the free-bFGF group at any time point (P< .05).
These results suggest that mGHMs/bFGF were distributed
equally and degraded slowly over 2 weeks after the intratra-
cheal administration. In contrast, the free-bFGF solution was
degraded rapidly and almost disappeared in the 3 days after
intratracheal administration.
Prevention of Progressive PH by mGHMs/bFGF
Survival (Figure 2). Survival curves indicated that
mGHMs/bFGF significantly improved the survival of rats
with progressive PH (P< .01; Kaplan–Meier method, log-
rank test). On day 70, 6 (100.0%) rats had survived in the
control group, and 1 (16.7%) survived in the vehicle,
0 (0%) in the free-bFGF, and 5 (83.3%) in the mGHMs/
bFGF groups (n ¼ 6 each).
Body weights. Body weights 3 weeks after the intratracheal
administration of the vehicle and free-bFGF groups were
significantly lower than that of the control group. However,
there was no significant difference between the control and
mGHMs/bFGF groups (272.9  4.9, 225.0  16.0, 228.3
 19.4, and 267.3  15.6 g for the control, vehicle, free-
bFGF, and mGHMs/bFGF groups, respectively; P< .01).
FIGURE 1. Release profile of the radioactivity remaining of basic fibro-
blast growth factor (bFGF) after intratracheal administration. The x-axis
shows the time course and the y-axis shows the percentage of the radioac-
tivity remaining in the lung. mGHMs/bFGF group (filles circles, solid
line), Gelatin hydrogel microspheres incorporating iodine 125–labeled
bFGF were injected into the trachea by using a pulmonary drug delivery de-
vice; free-FGF group (open circles, dotted line): free iodine 125–labeled
bFGF solution was injected into the trachea with the same device.1252 The Journal of Thoracic and Cardiovascular SRV pressure. RV/LV pressure ratios of the vehicle and
free-bFGF groups were significantly higher than that of
the control group, but there was no significant difference be-
tween the control and mGHMs/bFGF groups (0.35  0.04,
0.54  0.11, 0.58  0.21, and 0.36  0.05; P< .01 for the
control, vehicle, free-bFGF, and mGHMs/bFGF groups,
respectively; Figure 3, A).
RV hypertrophy. RV/LV plus septum weight ratios of the
vehicle and free-bFGF groups were significantly higher than
of the control group. However, there was no significant dif-
ference between the control group and the mGHMs/bFGF
group (0.27  0.04, 0.48  0.10, 0.50  0.04, and 0.27 
0.15; P < .01 for the control, vehicle, free-bFGF, and
mGHMs/bFGF groups, respectively; Figure 3, B).
Arterial gas analysis. Partial pressure of oxygen in arterial
blood of the vehicle and free-bFGF groups was significantly
lower than that seen in the control group. However, there
was no significant difference between the control group
and the mGHMs/bFGF group (82.2  3.6, 63.8  5.5,
67.1 12.3, and 80.6 6.1 mm Hg for the control, vehicle,
free-bFGF, and mGHMs/bFGF groups, respectively;
P< .05).
Histology. No bleeding or hematoma was observed after in-
tratracheal administration of mGHMs or mGHMs/bFGF.
FIGURE 2. Survival curves after a single intratracheal administration into
rats with progressive pulmonary hypertension. Survival curves are gener-
ated by means of Kaplan–Meier analysis. These results suggest that a single
intratracheal administration of microgelatin hydrogels microspheres incor-
porating basic fibroblast growth factor (mGHMs/bFGF) improved survival
of rats with progressive pulmonary hypertension. mGHMs group (open cir-
cles, small dotted line), Monocrotaline (MCT)–injected rats (a single subcu-
taneous injection of monocrotaline) treated with intratracheal administration
of plain mGHMs; free-FGF group (open circles, large dotted line), MCT-
injected rats treated with intratracheal administration of free-bFGF;
mGHMs/bFGF group (closed circles, solid line), MCT-injected rats treated
with intratracheal administration of mGHMs/bFGF (sustained-release
bFGF); control group, healthy rats treated with intratracheal administration
of 0.1 mL of saline (no circles, thin dotted line).urgery c November 2008
Hirose et al Cardiopulmonary Support and PhysiologyFIGURE 3. Right ventricular (RV)/left ventricular (LV) pressure ratio and RV/LV plus septum (LVþS)weight ratio. Panel A shows the RV/LV pressure ratio
for the evaluation of pulmonary hypertension 3 weeks after the treatment. Panel B shows the RV/LVþS weight ratio for the evaluation of RV hypertrophy.
Control group, Healthy rats treated with intratracheal administration of 0.1mL of saline; vehicle group, monocrotaline (MCT)– injected rats (receiving a single
subcutaneous injection of monocrotaline) treated with intratracheal administration of plain microgelatin hydrogel microspheres (mGHMs); free-FGF group,
MCT–injected rats treated with intratracheal administration of free basic fibroblast growth factor (bFGF); mGHMs/bFGF group, MCT-injected rats treated
with intratracheal administration of microgelatin hydrogel microspheres incorporating basic fibroblast growth factor (mGHMs/bFGF; sustained-release
bFGF).C
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PMedial wall thickness 3 weeks after treatment in the vehicle
and free-bFGF groups was significantly higher than that in
the control group and lower, although not significantly
lower, in the mGHMs/bFGF group than that in the vehicle
and free-bFGF groups (15.9%  1.8%, 23.4%  3.3%,
22.7% 4.6%, and 19.2% 3.1% for the control, vehicle,
free-bFGF, and mGHMs/bFGF groups, respectively).
Histologic sections of the lung tissue stained with von
Willebrand factor confirmed the increase in the number of
vessels and capillaries (Figure 4). The number of vessels
(diameter 50 mm) per square millimeter in the mGHMs/
bFGF group was significantly higher than that in the other
3 groups (5.3  2.4, 4.1  2.1, 7.3  2.8, and 18.8  7.1
vessels/mm2 for the control, vehicle, free-bFGF, and
mGHMs/bFGF groups, respectively; P< .01; Figure 5, A).
The number of small vessels, capillaries, or both (diameter
<50 mm) per square millimeter in the mGHMs/bFGF group
was also significantly higher than that in the other 3 groups
(65.5  16.6, 50.5  12.1, 87.7  17.5, and 161.0  43.3
capillaries/mm2 for the control, vehicle, free-bFGF, and
mGHMs/bFGF groups, respectively; P< .01; Figure 5, B).
These results indicate that a significant increase in the num-
ber of pulmonary vessels and vessel growth was achieved af-
ter a single intratracheal administration of mGHMs/bFGF.
DISCUSSION
For the study presented here, we newly developed
mGHMs that made intratracheal sustained release of bFGFThe Journal of Thoracic and Cafeasible. We were able to demonstrate that a single intratra-
cheal administration of mGHMs/bFGF led to an increase in
the number of capillaries and vessels in the lung and attenu-
ated PH and RV hypertrophy in rats with progressive PH.
Taken together, these findings suggest that a single intratra-
cheal administration of mGHMs/bFGF was effective for the
prevention of progressive PH in rats after MCT injection. To
the best of our knowledge, ours is the first study to use an
intratracheal sustained release system of angiogenic growth
factors for the prevention of progression of PH.
Although bFGF is one of themost potent mitogen-regulat-
ing proteins that induces angiogenesis and arteriogenesis
among growth factors, the biologic half-life of bFGF in its
free form is very short. To promote angiogenesis and arterio-
genesis in ischemic tissue with an angiogenic growth factor
requires a certain amount of time, whereas maintenance of
a significant tissue concentration of bFGF is crucial. In
fact, treatmentwith free-bFGF could not induce sufficient an-
giogenesis in an ovine tracheal autotransplantation model.18
This study showed that the biologic effect of bFGF in its free
form was limited but that mGHMs/bFGF was effective for
angiogenesis, arteriogenesis, or both in vivo. It was further
reported that in vivo gene transfection with a growth factor
through the pulmonary artery induced angiogenesis in the
rat lung.19 However, the problem remains whether sustained
protein delivery with genetic materials is safe.
Intratracheal administrationwas used as themethod for ad-
ministering mGHMs/bFGF in our study, and mGHMs/bFGFrdiovascular Surgery c Volume 136, Number 5 1253
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PFIGURE 4. Micrographs of the lung tissue.Micrographs of the lung tissue (stained with vonWillebrand factor, 1003magnification) 3 weeks after treatment
in rates with progressive pulmonary hypertension. Histologic sections of the lung tissue stained with von Willebrand factor confirmed the increase in the
number of vessels and capillaries. Micrograph I (left upper, control group), Healthy rats treated with intratracheal administration of 0.1 mL saline; Micrograph
II (left lower, vehicle group), monocrotaline (MCT)–injected rats (receiving a single subcutaneous injection of monocrotaline) treated with intratracheal ad-
ministration of plain microgelatin hydrogel microspheres (mGHMs); Micrograph III (right upper, free-FGF group), MCT-injected rats treated with intratra-
cheal administration of free basic fibroblast growth factor (bFGF); Micrograph IV (right lower, mGHMs/bFGF group), MCT-injected rats treated with
intratracheal administration of microgelatin hydrogel microspheres incorporating basic fibroblast growth factor (mGHMs/bFGF; sustained-release bFGF).were degraded slowly in the lung after administration. A sin-
gle administration through the pulmonary artery might be
one of the effective methods for administering mGHMs/
bFGF. However, pulmonary arterial administration of
mGHMs/bFGF can cause major pulmonary thrombosis
when the diameter of a microsphere is too large, or it can
pass through the lung and circulate through the whole body
when the diameter is too small. Determination of the diame-
ter of a microsphere is therefore critical for pulmonary
arterial administration. On the other hand, although intratra-
cheal administrationmight cause transient atelectasis in a lim-
ited part of the lung, tracheal thrombosis would improve as
the mGHMs degrade, and thus systemic invasiveness might
be limited. In fact, no complications, such as bleeding or
the deterioration of partial pressure of oxygen in arterial
blood gas, were found after intratracheal administration of
mGHMs/bFGF in our study. Because the serum concentra-
tion of bFGF after the intratracheal administration was
very low (data not shown), the systemic effect of bFGF, if
any, might be minimal. Nor were there any histologic
changes in tissues, such as the liver and kidney, after a single
intratracheal administration of mGHMs/bFGF in the prelim-
inary study. We therefore believe that intratracheal adminis-
tration of mGHMs/bFGF for PH can be used safely in the1254 The Journal of Thoracic and Cardiovascular Sclinical setting. The amount of bFGF obtained in the
mGHMswas determined based on the results of other studies
of angiogenesis with a single administration of mGHMs/
bFGF.11-14
It is tempting to speculate on the underlying mechanisms
as to why mGHMs/bFGF were effective for the rats with
MCT-induced PH in our study. MCT has been widely
used to establish an animal model of PH and reportedly in-
duces lung reactions, such as interstitial edema, inflamma-
tion, hemorrhage, and fibrosis.20 Subcutaneous injection of
MCT thus reduces the pulmonary vascular bed, leading to
an increase in pulmonary arterial blood pressure and severe
pressure overload–induced RV hypertrophy. A single intra-
tracheal administration of mGHMs/bFGF increased the
number of pulmonary vessels as a result of angiogenesis, ar-
teriogenesis, or both in the lung. We assume that these ef-
fects of mGHMs/bFGF in the severely injured pulmonary
vessels after MCT injection enhance the total pulmonary
vascular bed and reduce pulmonary arterial pressure. In ad-
dition, the results of the arterial gas analysis indicate that no
direct arteriovenous connections in the lung were formed af-
ter the single intratracheal administration of mGHMs/bFGF.
For clarification of the details of this mechanism, however,
further investigation will be necessary.urgery c November 2008
Hirose et al Cardiopulmonary Support and PhysiologyFIGURE 5. The number of vessels and capillaries. The left panel (A) shows the number of vessels (diameter>50 mm) per square millimeter, and the right
panel (B) shows the number of small vessels, capillaries, or both (diameter<50 mm) per square millimeter 3 weeks after treatment in rats with progressive
pulmonary hypertension.Control group, Healthy rats treated with intratracheal administration of 0.1 mL saline; vehicle group, monocrotaline (MCT)–injected
rats (receiving a single subcutaneous injection of monocrotaline) treated with intratracheal administration of plain microgelatin hydrogel microspheres
(mGHMs); free-FGF group, MCT-injected rats treated with intratracheal administration of free basic fibroblast growth factor (bFGF); mGHMs/bFGF group,
MCT-injected rats treated with intratracheal administration of microgelatin hydrogel microspheres incorporating basic fibroblast growth factor (mGHMs/
bFGF; sustained-release bFGF).C
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PWe did not evaluate the effects of intratracheal adminis-
tration of mGHMs/bFGF in normal murine lung. However,
we reported that subcutaneous injection of mGHMs/bFGF
in healthy animals enhanced vascularization and tissue gran-
ulation.21 Based on these findings, we speculate that intratra-
cheal administration of mGHMs/bFGF can also enhance
neovascularization in normal animal lung tissue. However,
further investigation will be necessary to prove this.
The main limitation of this experimental study is that we
used MCT-treated rats for our experimental model, which
might mean that the PH was more progressive than that
seen in human subjects. It was reported that bFGF levels
were increased during the development of MCT-induced
PH in rats.22 Of course, we believe that the level of bFGF re-
leased from mGHMs/bFGF after intratracheal administra-
tion in this study is much higher than the level of bFGF
released from endothelial cells intrinsically. Additional in-
vestigations with other animal PH models with pathologic
features more similar to those of human patients with PH
are necessary before human studies of this method can be
initiated.
The second limitation is that this is a ‘‘prevention’’ study.
It is very important to evaluate the effect of the intratracheal
administration ofmGHMs/bFGF in a ‘‘treatment’’ study.We
have some plans to investigate ‘‘later administration’’ with
‘‘advanced’’ PH models in other animals in the next series.
Our strategy with mGHMs/bFGF for the prevention from
progression of PH is intended to be combined with cardiacThe Journal of Thoracic and Csurgery. The therapeutic approach developed by us has the
potential to improve lung conditions (or prevent progression
of PH) before surgical intervention, such as staged opera-
tions for Fontan candidates in the clinical setting. Although
our intratracheal administration method involved injection
of the solution with mGHMs/bFGF into the trachea with
a pulmonary drug delivery device, it might be necessary to
develop mGHMs further so that for clinical use they can
be inhaled into the trachea in aerosol form.
In conclusion, a single intratracheal administration of
mGHMs/bFGF increased the number of vessels in the lung
and improved hemodynamics and survival with potential
improvement of gas exchange in rats with MCT-induced
PH. These findings indicate an important role for
mGHMs/bFGF in angiogenesis, arteriogenesis, or both in
the lung and suggest that this therapeutic approach might
provide a novel treatment strategy for patients with primary
or secondary PH because this noninvasive treatment is es-
sentially topical, with negligible systemic effects.
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